1. Home
  2. EVER vs REPL Comparison

EVER vs REPL Comparison

Compare EVER & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EverQuote Inc.

EVER

EverQuote Inc.

HOLD

Current Price

$24.81

Market Cap

929.5M

Sector

Technology

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$8.41

Market Cap

781.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVER
REPL
Founded
2008
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
929.5M
781.3M
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
EVER
REPL
Price
$24.81
$8.41
Analyst Decision
Strong Buy
Buy
Analyst Count
4
9
Target Price
$33.00
$12.00
AVG Volume (30 Days)
330.6K
1.3M
Earning Date
02-23-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
284.14
N/A
EPS
1.44
N/A
Revenue
$644,656,000.00
N/A
Revenue This Year
$36.72
N/A
Revenue Next Year
$13.63
N/A
P/E Ratio
$17.59
N/A
Revenue Growth
57.83
N/A
52 Week Low
$17.20
$2.68
52 Week High
$30.03
$14.80

Technical Indicators

Market Signals
Indicator
EVER
REPL
Relative Strength Index (RSI) 38.12 32.90
Support Level $26.45 $8.23
Resistance Level $27.47 $9.99
Average True Range (ATR) 0.79 0.42
MACD -0.37 -0.23
Stochastic Oscillator 15.99 7.58

Price Performance

Historical Comparison
EVER
REPL

About EVER EverQuote Inc.

EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: